PECAM1 and neoplasm: Immunostaining and quantitation of endothelial (VE-CADHERIN/CD31) and pericyte (DESMIN/aSMA) marker expression in tumor cells (GFP) showed a significant reduction in radiated, EP300-deficient tumors compared to radiated and untreated EP300-deficient or control tumors (Fig. 7i, j and Supplementary Fig. 7h, i).